It has been demonstrated that subsets of HER2 and basal breast cancers are highly sensitive to neo-adjuvant chemotherapy, displaying a four- to sixfold increase in pathologic complete response (CR) relative to luminal tumors. This evidence concerns the gene ERBB2 and breast carcinoma.